{
    "nctId": "NCT00106002",
    "briefTitle": "Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Breast Neoplasms, Male, Carcinoma, Ductal",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "Overall Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have been diagnosed with either advanced or metastatic breast cancer.\n* Chemotherapy has not been given for advanced or metastatic breast cancer.\n* The diagnosis of advanced or metastatic breast cancer was made at least 12 months after chemotherapy was given after breast surgery.\n* Able to carry out work of a light nature (for example, light housework, office work).\n* Must be at least 18 years old.\n\nExclusion Criteria:\n\n* Have received prior bone marrow or peripheral stem cell transplantation.\n* Have received prior chemotherapy for metastatic breast cancer.\n* Are currently pregnant or breast-feeding.\n* Have an active infection that your doctor decides will affect your safety.\n* Are unable to take folic acid or vitamin B12.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}